LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients

AIDS

Volumn 26, Issue 8, 2012, Pages 1009-1015

  Rivero Juarez, Antonio ^a,b   Camacho, Angela ^a,b   Caruz, Antonio ^c   Neukam, Karin ^d   Gonzalez, Rafael ^a,b   Di Lello, Federico A ^d   Perez Camacho, Ines ^e   Mesa, Pilar ^c   Torre Cisneros, Julian ^a,b   Peña, José ^a,b   Pineda, Juan A ^d   Rivero, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL DE PONIENTE   (Spain)

Author keywords

hepatitis C virus; HIV; IL28B; low density lipoprotein receptor; pegylated interferon; ribavirin; viral kinetics

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN RECEPTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; FEMALE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SUPERINFECTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, LDL; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84861101017     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283528b1c     Document Type: Article

References (24)

1. Rivero-Juarez A, Camacho A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, et al. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV coinfected patients with genotype 1 or 4. J Antimicrob Chemother [Epub ahead of print].
2. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-129.
3. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9:344-350.
4. Howell CD, Gorden A, Ryan KA, Thompson AJ, Ibrahim C, Fried M, et al. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol 2011. doi: 10.1016/j.jhep.2011.10.004.
5. Pineda JA, Caruz A, Rivero A, Neukan K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788-795.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461:399-401.
7. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog 2007; 3:1017-1022.
8. Ogawa K, Hishiki T, Shimizu Y, Funami K, Sugiyama K, Miyanari Y, et al. Hepatitis C virus utilizes lipid droplet for production of infectious virus. Proc Jpn Acad Ser B 2009; 85:217-228.
9. Dai CY, Chuang WL, Ho CK, Ou TT, Huang JF, Hsieh MY, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study. J Hepatol 2008; 49:9-16.
10. Miyazaki T, Honda A, Ikegami T, Saitoh Y, Hirayama T, Hara T, et al. Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state-an epidemiological survey of a large Japanese cohort. Hepatol Res 2011; 41:530-541.
11. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasusi Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010; 40:251-260.
12. del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, et al. Baseline serum low-density lipoprotein cholesterol levels predict sustained virological response to pegylated interferon plus ribavirin in HIV/Hepatitis C virus-coinfected patients. AIDS 2008; 22:923-930.
13. Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K, et al. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 2011; 25:1415-1420.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis management and treatment of hepatitis C: An update. AASLD Practice Guidelines. Hepatology 2009; 49:1335-1374.
15. Burlone ME, Budkowska A. Hepatitis C virus cell entry: Role of lipoproteins and cellular receptors. J Gen Virol 2009; 90:1055-1070.
16. von Hahn T, Rice CM. Hepatitis C virus entry. J Biol Chem 2008; 283:3689-3693.
17. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008; 10:821-827.
18. Pietschmann T. Virology: final entry key for hepatitis C. Nature 2009; 457:797-798.
19. Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009; 14:45-54.
20. Zhang L, Jilg N, Shao R-X, Lin W, Fusco DN, Zhao H, et al. IL28B inhibits hepatitis C virus replication through the JAKSTAT pathway. J Hepatol 2011; 55:1-10.
21. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic Hepatitis C. Hepatology 2010; 52:1888-1896.
22. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57:516-524.
23. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85:303-315.
24. Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, et al. Differences in virological response to pegylated interferon plus ribavirin between hepatitis C virus (HCV)-monoinfected patients and HCV-HIV-coinfected patients. Antivir Ther 2008; 13:1047-1055.